Cancer cells generate harmful substances as they grow, and managing those by-products without disturbing their broader redox balance is an ongoing challenge. A new study examines how cells resolve this trade-off, focusing on formaldehyde, a genotoxic one-carbon by-product, and its relationship to the cell’s wider antioxidant defenses.

The KEAP1–NRF2 pathway, a central regulator of antioxidant defenses, is frequently hyperactivated in cancer. Formaldehyde is typically neutralized with the help of glutathione, a molecule that is also required to suppress ferroptosis, a form of cell death triggered by damage to fats in the cell membrane. Because both tasks draw on the same glutathione supply, a cell that spends glutathione detoxifying formaldehyde has less left over to guard against ferroptosis.

Researchers led by Lucas Pontel at the Josep Carreras Leukemia Research Institute found that NRF2 resolves this trade-off by raising levels of SLC7A11, a transporter protein that brings the molecule cystine into the cell. This opens up a way of tolerating formaldehyde that works largely independent of glutathione, leaving the glutathione supply free to keep suppressing ferroptosis. Once inside NRF2-active cells, cystine is converted into cysteine, which reacts with formaldehyde to form a stable thiazolidine conjugate, a compound the researchers were able to detect directly in cancer cells.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

That same arrangement also exposes a vulnerability. When the researchers combined formaldehyde stress with inhibition of SLC7A11, the combination activated the integrated stress response inside the cells, suppressed their overall protein synthesis, and sharply reduced cell viability. Pairing drugs that block cystine uptake with drugs that block glutathione synthesis killed leukemia cells as well as several types of solid tumor cells, including lung, colon, and brain tumor cells. 

The findings point toward a possible treatment strategy for leukemia in particular. Among patients with myeloid leukemia, higher levels of SLC7A11 are linked to worse survival, raising the possibility that these cancers depend on the same defense system identified in the study. The researchers plan to investigate next whether disabling that system could become a safe and effective treatment.